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Introduction: Huntington’s disease (HD) is a currently incurable, autosomal dominant 
neurodegenerative disease caused by an abnormally long polyglutamine tract in the 
huntingtin protein. As this mutation causes disease via gain-of-function, lowering 
huntingtin levels represents a rational therapeutic strategy.  
Areas covered: We searched MEDLINE, CENTRAL and other trial databases, and 
relevant company and HD funding websites for press releases until April 2020 to review 
different strategies for huntingtin lowering, including autophagy and PROTACs, which 
have been studied in preclinical models. We focussed our analyses on oligonucleotide 
(ASOs) and miRNA approaches, which have entered or are about to enter clinical trials.  
Expert opinion: ASO and mRNA approaches aiming to lower mutant huntingtin 
protein production and strategies aiming to increase mutant huntingtin clearance are 
attractive, as they target the cause of disease. However, these strategies present some 
unresolved questions, including the optimal mode of delivery and associated safety 
issues. It is unclear if the human CNS coverage with intrathecal or intraparenchymal 
delivery will be sufficient for efficacy. The extent that one needs to lower mutant 
huntingtin levels for it to be therapeutic in relation to disease course is uncertain. 
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1.1.  Introduction to Huntington’s disease 
Huntington disease (HD) is an autosomal dominant neurodegenerative disease that manifests 
with abnormal movements, including chorea, cognitive impairment and psychiatric 
disturbances. While HD can strike at any age, its median age-of-onset is around 40 years of 
age. It has a prevalence of 3-10/100,000 in populations of European descent but varies a lot 
in different ethnic groups and countries [1]. Pathologically, the disease causes neuronal loss 
in many brain regions, particularly the caudate, putamen and cortex. Currently, while there 
are treatments that have some impact on the motor signs of the disease (like tetrabenazine for 
chorea), there are no proven disease-modifying therapies.  
 
HD is caused by a CAG trinucleotide repeat expansion at the N-terminus of the huntingtin 
gene (HTT), which encodes an expanded polyglutamine tract in the huntingtin protein. The 
polyglutamine tract length is polymorphic in different wild-type alleles and expansions of 38 
or more successive glutamines can cause disease. There is an inverse correlation between the 
polyglutamine tract length and age-at-onset of disease.  
 
HD is characterised by the formation of neuronal inclusions/aggregates comprising mutant 
huntingtin and other proteins associated with it. In rare juvenile-onset HD, the aggregates are 
found in the nucleus, while in most adult-onset cases the aggregates are seen in the 
cytoplasm. While there has been discussion as to whether the large aggregates are toxic or 
relatively protective compared to the “soluble” protein [2,3], the toxicity does seem to be 
associated with the propensity of the mutant protein to aggregate and it is possible that the 
process of aggregation is a key component of toxicity. 
 
Extensive data argue that the HD mutation causes disease predominantly via gain-of-function 
mechanisms at the protein level [4]. These include mouse studies showing that hemizygous 
loss-of-function of huntingtin is well tolerated, while mutant transgenes expressed on a wild-
type background cause HD-like pathologies. Importantly, switching off mutant huntingtin 
expression results in a reversal of signs of disease in a conditional mouse model  [5], as is 
also seen with a Cre-Lox-mediated excision of mutant exon 1 of huntingtin with the 
polyglutamine expansion in a BAC mouse model [6].  It may be beneficial to reduce mutant 
huntingtin levels not only in neurons but also in astrocytes and oligodendrocytes [7,8]. 
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Accordingly, strategies for lowering mutant huntingtin have been explored for therapeutic 




2.. Increasing mutant huntingtin degradation  
2.1. Introduction to huntingtin degradation pathways 
One approach that can lower mutant huntingtin is to enhance its degradation. Mutant 
huntingtin can be degraded by macroautophagy (henceforth autophagy) or the ubiquitin-
proteasome pathway. Macroautophagy (generally referred to as autophagy) is a bulk 
degradation system that engulfs proteins or organelles into double-membrane 
autophagosomes associated with microtubule-associated protein 1A/1B light chain 3 (LC3),  
for subsequent lysosomal degradation [9,10]. The clearance of mutant huntingtin has a much 
greater dependence on autophagy than the wild-type protein. The ubiquitin-proteasome 
system (UPS) can also assist mutant huntingtin degradation, but this pathway cannot clear 
oligomeric or higher-order aggregated forms of the protein, as the narrow entrance to the 
proteasome requires substrates to be monomeric and unfolded in order to pass through. 
However, there clearing monomeric forms is likely to have benefit.  
 
2.2. Autophagy 
Inhibition of the mammalian target of rapamycin complex 1 (mTORC1), which negatively 
regulates the autophagic pathway, using rapamycin, an inhibitor of mTOR, and CC1-779, an 
analog of rapamycin, enhanced the clearance of  mutant huntingtin, resulting in decreased 
toxicity in cell, fly and mouse models of HD [11,12]. Similarly, induction of autophagy 
through mTOR-independent pathways facilitates the clearance of mutant huntingtin in 
mammalian cell, fly and zebrafish models [13,14], indicating that autophagy induction may 
be a rational therapeutic strategy for HD through lowering mutant huntingtin [15-19].  
 
The clinical approach exploiting autophagy has been encouraged by recent repurposing 
studies using felodipine, an L-type calcium channel blocker that crosses the blood-brain 
barrier (BBB) that induces autophagy though an mTOR-independent pathway [13]. In this 
study, felodipine induced autophagy and lowered mutant huntingtin and other autophagy 
substrates when the drug was administered via subcutaneous minipumps in mice in order that 
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their plasma drug concentrations mimicked those seen in humans taking the drug at standard 
doses for its conventional antihypertensive use. This compound also protected against mutant 
htt toxicity in mice [20]. Thus, it may be possible to induce autophagy in mammalian brains 
with compounds that are already in clinical use that are neuroprotective in HD models.  
 
2.3. Autophagosome-tethering compound (ATTEC) 
Since mutant htt is degraded by autophagy, molecular glue-like molecules have also been 
developed that interact with both mutant htt and autophagosome-associated LC3 and by so 
doing facilitate engulfment of mutant HTT by autophagosomes [21] (Figure 1). These so-
called autophagosome-tethering compounds (ATTEC) enhance mutant htt degradation via 
autophagy. ATTECs can cross the blood-brain barrier and lower mutant HTT without 
affecting WT htt in cultured neurons and in vivo brain tissue, thereby ameliorating mutant htt 




The UPS can also be exploited to target specific substrates for degradation via proteolysis-
targeting chimeras (PROTACs) [22]. This approach utilises E3 ligase ligands that are fused 
through a flexible chemical linker to another ligand that binds a target protein, in order to 
induce artificial ubiquitination, leading to degradation of the protein by the proteasome 
(Figure 2). In this way, PROTACs provide the potential for rapid and targeted degradation of 
proteins to which one generates a specific ligand. Hybrid molecules that bind a ligand for a 
ubiquitin E3 ligase (cellular inhibitor of apoptosis protein 1; cIAP1) to ligands for mutant 
HTT, reduced levels of mutant HTT through induction of selective degradation by the 
proteasome in cell lines [23].  
 
3. Reducing mutant huntingtin synthesis 
3.1. Introduction to strategies that may reduce huntingtin synthesis 
 
As a monogenic disorder, HD pathology results from translation of mutant huntingtin, which 
has allowed development of targeted therapies along this pathway. Although gene editing 
would seem the logical place to start by using zinc finger nucleases or CRISPR-Cas9 [24], 
the tools for doing this across the human brain with the required fidelity are not currently 
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available, although these are being developed [25]. Some groups have investigated whether 
one can target huntingtin gene expression epigenetically through histone deacetylase 
inhibitors. This is being assessed in a phase 1 clinical trial in South Korea using CKD-504 
(NCT03713892) and was investigated  using phenylbutyrate in a Phase 1 trial (NCT 
00212316) [26]. 
 
The feasibility of reducing mutant huntingtin synthesis as a therapeutic strategy for HD has 
been supported by a series of different RNAi experiments in HD animal models [27]. 
Cleveland and colleagues showed that antisense oligonucleotides lowered both wild-type and 
mutant htt in 3 different mouse models of HD and thereby ameliorated signs of disease. They 
also reported effective huntingtin lowering in a non-human primate, and thereby set the scene 
for antisense therapeutics for HD [28]. 
 
As a result, a number of non-selective and selective DNA and RNA gene-silencing or gene-
editing approaches for lowering mHTT are being explored, some of which have now entered 
clinical trials. Non-selective approaches, including some antisense oligonucleotides (ASO), 
will lower both mutant and wild-type huntingtin (wtHTT) proteins. The advantages and 
disadvantages of this strategy are unknown, as the impact of lowering wtHTT in people has 
not been extensively explored [29] outside of early clinical trials with ASO therapies (see 
below) and rare individuals with isolated genetic abnormalities within the HD gene [30]. In 
animal models, studies initially suggested that knocking down wtHTT has no deleterious 
consequences in the mammalian brain [31], but more recently it has reported that huntingtin 
is needed for both striatal cell survival and connectivity [32] and for regeneration at other 
sites in the adult CNS [33]. As such, allele-selective lowering of mHTT (e.g. using viral-
encoded small interfering RNAs (siRNAs) and microRNAs ) may be a safer option, as this 
will preserve wtHTT levels.  
 
3.2. Antisense oligonucleotides (ASO) 
ASOs are short, single-stranded synthetic oligomers that are made up of nucleotides which 
bind to specific sections of RNA. The purpose of ASOs is to either enable degradation of the 
target RNA, or terminate its translation. The nucleotides may be chemically modified to 
facilitate specific enzymatic functions following binding with the target RNA. In preclinical 
experiments with HD models, ASOs have demonstrated dose-dependent lowering of mHTT 
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by arresting translation of the mutant protein, resulting in long-lasting phenotypic and 
survival benefits [28,34-36]. This has now led to clinical trials which are discussed in more 
detail below [37]. 
 
3.2.1. HTTRX / RG6042 
RG6042 (initially known as HTTRX) is an ASO developed by IONIS Pharmaceuticals to 
degrade the target RNA sequence that encodes huntingtin. RNA degradation is facilitated by 
triggering of RNase H1 once the ASO has bound to the target RNA, thereby reducing  
translation of both mHTT and wtHTT. RG6042 is the first such putative disease-modifying 
therapy using this strategy that has been trialled in HD. In order for the drug to work at the 
site where it is needed, it had to be delivered intrathecally, which is associated with logistical 
as well as compliance issues, especially as injections are currently given every few months.  
 
The first-in-human HD clinical trial with RG6042 had a randomised, double-blinded, 
placebo-controlled multiple ascending dose design and was published in 2019 [38]. This 
international multicentre phase I/IIa study evaluated RG6042 in early-stage HD patients 
(n=46). The participants were randomised in a 3:1 ratio to receive either the ASO or placebo 
every 4 weeks over a 4-month period via intrathecal injection, followed by a 4-month follow-
up period with no dosing. Cerebrospinal fluid (CSF) samples were collected at each dosing 
visit prior to administering the RG6042, and a further CSF sample was collected during the 
follow-up period. Repeated intrathecal administration of RG6042 was found to be well-
tolerated over this short period of time and resulted in a dose-dependent reduction in CSF 
mHTT concentrations. Clinical efficacy could not be assessed in such a small short-term trial, 
but treatment did lead to a paradoxical increase in CSF neurofilament light chain levels, as 
well as ventricular volume - both of these measures are thought to be associated with greater 
neuronal loss.  
 
At the conclusion of this trial, an open-label extension study was initiated where all 
participants who completed the initial study were invited to participate and were dosed with 
RG6042 either every 4 or 8 weeks (NCT03342053). The results of this study have yet to be 
formally published although the 15-month data have been presented at meetings and continue 
to show  ~70% reduction in CSF mHtt levels in the higher frequency dose group 
(https://chdifoundation.org/2020-conference/#schobel). A further open-label extension study 
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using this same patient cohort was commenced in October 2019 but dosing was reduced in 
frequency to either every 8 or 16 weeks, in view of some of the adverse events that were seen 
with the more frequent dosing regime (NCT03842969). 
 
In parallel to these open label studies, an international, randomised, double-blinded, 
multicentre, pivotal phase III trial to evaluate efficacy and safety of RG6042 commenced in 
January 2019 (n=909) (GENERATION HD1, (NCT03761849). Recruitment  concluded in 
April 2020 and the trial is expected to finish in 2022. The results of this trial will be 
instrumental in determining whether this ASO may offer true disease-modifying benefit to 
patients with early HD. 
 
3.2.2. WVE120101 and WVE-120102 
 
One of the theoretical disadvantages of RG6042 (above) is its inability to discriminate between 
the pathological allele and the normal allele. This is important, since complete loss of 
huntingtin in embryogenesis and early postnatal stages causes neurodegeneration in mice [39]. 
While neuronal loss of huntingtin in adult mice appears to be well tolerated, huntingtin has 
functions relevant to nervous system maintenance [39], and the medium- and long-term effects 
of reducing overall huntingtin levels in humans are unclear. To avoid this, allele-selective 
ASOs, such as WVE-120101 and WVE-120102 have been developed to selectively target the 
mHTT gene and not the wild-type allele, acting at the U variant of the single nucleotide 
polymorphism (SNP) rs362307 (SNP1) and the U variant of SNP rs362331 (SNP2) [40]. The 
company estimates that about 2/3rds of HD patients will be heterozygous for one of these SNPs 
and thus will be eligible for treatment with this agent. This therapy has now progressed to 2 
clinical trials, PRECISION HD1 (NCT03225833) and PRECISION HD2 (NCT03225846), 
which have tested WVE-120101 and 120102, respectively, in a multicentre, randomised, 
double-blinded, placebo-controlled fashion in patients with early manifest HD. The interim 
results of these trials, after short periods of treatment, have been made public through press 
releases but both trials are still ongoing and no peer-reviewed publication has appeared to date. 
In both trials, the agent appears to be well tolerated (with no serious adverse events reported) 
with a dose-dependent reduction in CSF mutant huntingtin levels of around 12% [41] with no 
difference seen in the level of CSF neurofilament light chain.  The relatively modest reduction 
in CSF mtHTT levels has now led the company to test higher doses of its therapeutic agents in 
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both of these ongoing trials with “topline results” expected in the second half of 2020, although 
this may be delayed because of the current COVID-19 virus pandemic. 
 
3.3. MicroRNAs against huntingtin 
3.3.1. AMT-130 
Another approach being taken by a company called uniQure is to use an AAV5 vector to 
deliver a specific microRNA into selective brain areas (striatum) which works to inhibit the 
production of mtHTT [37], especially the toxic exon1 HTT fragment. This approach has been 
trialled preclinically in human iPSC models, as well as in transgenic mice [42] and more 
recently minipigs [43]. In these latter studies, it was shown that convection enhanced delivery 
of the agent to the porcine striatum, leading to significant effects on mutant huntingtin 
expression 6 and 12 months post-injection. The reductions in mtHTT were highly significant 
at around 80-85% in the caudate and putamen with smaller reductions in the amygdala, 
thalamus and cortex, along with a 30% reduction in CSF mtHTT levels. The first in-human 
clinical trial using this approach has now commenced in the US with the first 2 patients 
enrolled and treated in June 2020 (NCT04120493). This trial is designed to compare 2 doses 
of AMT-130 in 26 patients over 18 months, 16 of whom will receive the active agent and 10 
sham surgery.  
 
3.3.2. VY-HTT01 
A similar therapeutic approach to AMT-130 is being developed by Voyager Therapeutics in 
collaboration with Sanofi-Genzyme and the CHDI foundation. As for AMT-130, this again 
uses an AAV vector to deliver a miRNA against HTT and has been shown to work in mouse 
models of HD [44], as well as non-human primates [45], with reductions of HTT protein 
levels of up to 50% in various brain regions. As a result, the company are now filing to take 
this agent to clinical trials [46], which will be done on the back of an observational cohort 
study in peri-manifest patients, who are thought most likely to benefit from the early phase 
trials with this agent. 
 
3.4. Other agents being developed: 
Other companies working on therapies designed to lower huntingtin include Vybion, who are 
working on an intrabody (INT41) that will be delivered using an AAV virus; PTC 
Therapeutics and Novartis who are aiming to develop an oral therapy designed to lower 
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huntingtin mRNA; Takeda and Sangamo who are trying to develop zinc finger nucleases to 
target the mHtt gene; and Biomarin who are aiming to develop an anti-sense oligonucleotide 
(ASO) that targets CAG repeats in all genes not just huntingtin. (More details can be found 
on these agents at https://hdsa.org/hd-research/therapies-in-pipeline/#).  
 
4. Conclusion 
As Huntington’s disease is caused primarily by a gain-of-function mutation, this disease may 
be ameliorated by strategies that either reduce the synthesis or enhance the degradation of 
mutant huntingtin. Early clinical studies with antisense oligonucleotides suggest that 
huntingtin lowering can be achieved relatively safely over a 15 month period and follow-up 
studies are in progress. In parallel, other antisense oligonucleotide and miRNA studies are 
about to enter the clinic. Preclinical studies are revealing a number of strategies that can be 
used to enhance huntingtin clearance using small molecules/non-nucleic acid strategies. 
Thus, this is a rapidly moving field and promising progress is occurring on both the clinical 
and preclinical fronts.  
 
5. Comment 
The approaches looking to lower mutant huntingtin protein production are clearly attractive 
as a therapeutic strategy in HD as they target the root cause of the disorder. However, there 
are a number of unresolved questions with this approach at the moment and these include: 
(i) Mode of delivery of ASOs and iRNAs, as these require either repeated intrathecal 
injections or a single intrastriatal injection. Both of these procedures are invasive and are not 
without complications, in particular with repeated lumbar punctures, as problems can arise 
due to fibrosis around the site of needle insertion and drug administration. In addition, the 
ASO backbone can induce a chemical meningitis in some patients (personal observation). 
Oral drug repurposing approaches avoid such issues assuming the drug can get into the CNS 
at therapeutic doses. 
(ii) Coverage of the CNS is limited with current approaches. With intrathecal injections, it is 
unlikely that the ASO can penetrate deep within the adult brain parenchyma and for 
stereotactic injections of AAV-delivered agents, the volume of distribution will be even more 
limited to the target structure. However, at least in preclinical studies with AMT 130, there is 
some axonal transport away from the site of injection with AAV delivery, which would 
increase the brain areas exposed to the therapeutic. However, it is unknown whether such 
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axonal transport occurs in HD, given problems that have been reported in this disease state 
[47]. Again orally-administered blood-brain- barrier-penetrating agents avoid such issues 
given the less invasive nature of their administration and the fact that in theory all cells in the 
CNS will be exposed to them via the circulation.  
(iii) Degree and extent that one needs to lower mutant huntingtin levels for it to be 
efficacious in relation to disease course. In mouse models of HD, transient reductions of htt 
lead to sustained improvements [28]. However, what this means in the clinical setting is 
unknown and has major implications for the frequency and dosing of patients, which is likely 
to be required over decades. With this also comes financial implications – e.g. the ASO 
therapy for spinal muscular atrophy costs $750,000 for the first year and $375,000 per year 
thereafter.  
(iv) Stage of disease to target therapeutically. This partly relates to point iii above, in that 
the extent to which one needs to lower huntingtin to achieve clinical benefit likely depends 
on the stage when lowering is induced in relation to the disease course – one may be able to 
delay onset of disease if one lowers huntingtin modestly but long before the expected age-of-
onset. On the other hand, one may need greater degrees of huntingtin lowering to achieve 
clinical benefits, if one initiates this strategy well into the clinical course. Indeed, there may 
be a point in the disease after which huntingtin lowering has no effect on the clinical 
trajectory [48], similar to what has been described with mouse models of another 
polyglutamine disease, spinocerebellar ataxia type 1 [49]. Ideally one would seek a strategy 
that could be employed at an early stage to delay the onset of disease. This is particularly 
feasible in HD, when most cases have family histories and most individuals at risk can be 
identified. While challenges remain in order to gain regulatory approval in such scenarios, 
there has been considerable progress in identifying biomarkers of early premanifest disease in 
HD [50]. Thus, this disease is better placed than most for developing disease-delaying agents. 
That being said, there are likely to be limits on when one can start such therapies including in 
paediatric populations. Such individuals are typically excluded from trials because of issues 
around consent and in part because these patients possess very high CAG repeats with a more 
aggressive clinical course. Thus, it is unknown whether these huntingtin-lowering strategies 
will be effective in these cohorts as in older patients with less aggressive disease. 
Interestingly, elderly populations are also excluded, although paradoxically these patients 
appear to advance less rapidly that those with younger onset disease [51]. 
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(v) Extent to which one needs to retain near-normal levels of wild type Htt for CNS 
function to not be affected is unknown and thus it is unclear whether allele specific 
approaches are really needed. This is a particularly important issue when comparing the AAV 
approaches, which results in irreversible loss of HTT, versus the ASO strategy, where the 
depletion is only ever transient, versus oral drug clearance therapies where the drug can 
easily be discontinued. 
(vi) Extent to which one needs to treat peripheral Htt expression. 
The huntingtin gene is expressed throughout the body with a number of clinical features that 
may relate to its expression outside the CNS, such as weight loss, metabolic disturbances and 
muscle atrophy [52,53].  CNS-targeted therapies are unlikely to affect expression of mtHTT 
peripherally, which again would argue for the advantages of oral systemically-delivered 
therapies that also have significant CNS penetration. However, the added benefits of 
lowering mutant huntingtin in the whole body versus the brain alone are not known.  
 
Overall agents that directly seek to lower huntingtin in the adult HD brain hold great promise 
and could be combined with agents that seek to enhance the clearance of mtHTT, such as up-
regulators of autophagy. Indeed, such a combined approach has some clear advantages as it 
would enable: 
(i) the ASO therapies to be given less frequently, which would have much implications 
for improving compliance and costs of such an approach;  
(ii) and for AAV miRNA therapies they could be given in lower doses, which would 
enable larger margins of safety around concerns over the irreversible loss or 
reduction in CNS huntingtin levels. 
However, the multisystem nature of Huntington’s disease, and the currently unresolved 
questions about the efficacy and safety of various huntingtin-lowering strategies, suggests 
that it will be wise to continue exploring other therapeutic strategies for this disease. Indeed, 
polypharmacy may be powerful both for ameliorating signs and symptoms in affected 







Huntington’s disease is an autosomal dominant disease caused by a gain-of-function mutation 
 
Extensive data in preclinical models argues that lowering mutant huntingtin levels may 
ameliorate disease onset and progression 
 
Huntingtin levels can be lowered by either enhancing degradation via autophagy of the 
ubiquitin-proteasome routes, strategies supported in preclinical models or reducing its 
formation via allele-specific oligonucleotides or mRNAs, strategies that are being tested in 
the clinic. 
 
Current data suggest that these approaches are not associated with overt liabilities in the 
short-term and could in theory be combined. 
 
New technologies and approaches being developed will lead to refinement of approaches 
leading to huntingtin lowering and have the potential to bring strategies aiming to enhance 
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Figure 1. Schematic showing Autophagosome-tethering compound (ATTEC). These 
molecules act by tethering targets like mutant huntingtin to LC3, a component in the 




Figure 2. Schematic illustrating the principle behind PROTACs. These comprise E3 ligase 
ligands that are fused through a flexible chemical linker to another ligand that binds a target 
protein, in order to induce artificial ubiquitination, leading to degradation of the protein by 




Drug name Phase Indication Pharmacology description Route of administration Pivotal trials 
RG6042 Phase III ongoing Allele non-selective 








Phase I/II ongoing 
Phase I/II ongoing 
Allele-selective 
Degradation of mtHTT RNA 
recognized with ASO via specific 





AMT-130 Phase I/II ongoing 
Allele non-selective 
Injection into the brain 
Degradation of HTT RNA 
targeted with a microRNA 
Intrastriatal injection NCT04120493 
VY-HTT01 Preclinical study 
Allele non-selective 
Injection into the brain 
Inhibition of HTT production 
through RNA interference 
Injection into thalamus 
and putamen 
Ref [44, 45] 


